Abstract: The present invention relates to a combined preparation comprising (i) a modulator of pyruvate kinase M2 (PKM2) activity, and (ii) an agent providing high mobility group box 1 (HMGB1) polypeptide or a derivative thereof. The present invention also relates to the aforesaid combined preparation for use as a medicament and for use in the treatment of inappropriate cellular proliferation, preferably in the treatment of cancer. Moreover, the present invention relates to a method for determining whether a subject suffering from inappropriate cellular proliferation is amenable to a treatment comprising administration of a modulator of PKM2 activity as the only PKM2 inhibitor and to treatment methods related thereto.

Abstract: The present invention relates to a polynucleotide comprising an expressible nucleic acid sequence encoding a relaxin family peptide receptor (RXFP) polypeptide for use in treatment and/or prevention of heart failure in a subject. The present invention further relates to a vector comprising the polynucleotide of the present invention for use in treatment and/or prevention of heart failure, as well as to host cells, RXFP agonists, kits and devices related thereto.

Abstract: The present invention relates to a method of making an oral dosage form comprising the steps of reacting at least one cell penetrating peptide (CPP), purifying CPP-lipid conjugates, processing a lipid batch to obtain CPP-modified liposomes and incorporating a liposome lyophilisate into an oral dosage form. The present invention further relates to oral dosage forms and oral dosage forms for use in a therapeutic method.

Abstract: The present invention relates to cyclic peptide compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine-containing protein. Preferred scavenger compounds are said cyclic peptides comprising a specific amino acid motif and a hydrophobic modification, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the cyclic peptides as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the cyclic peptides for the prevention and/or treatment of a disease caused by or associated with methylglyoxal (MG) and/or reactive carbonyl species (RCS), in particular caused by or associated with elevated MG levels, such as diabetes and its associated complications, cardiovascular diseases and obesity.

Abstract: The invention refers to a method for in vitro diagnosis of a severe infection comprising determining delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein in a biological sample wherein an elevated level of expression of delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein is indicative of a severe infection; and the use of delta-like ligand 1 protein as a biomarker for in vitro diagnosis of a severe infection such as sepsis.

Abstract: The present invention relates to a high mobility group box 1 (HMGB1) polypeptide, wherein in said HMGB1 polypeptide at least one, preferably two, more preferably three, most preferably all four tyrosine residues at positions corresponding to amino acid positions Y109, Y144, Y155 and/or Y162 of human HMGB1 have been exchanged to an amino acid residue independently selected from glutamic acid, glutamine, aspartic acid, asparagine, homoglutamic acid (2-aminohexanedioic acid), and homoglutamine (2,6-diamino-6-oxohexanoic acid). The present invention further relates to a polynucleotide encoding a polypeptide according to the present invention, to a vector comprising said polynucleotide, and to a host cell comprising said polypeptide, said polynucleotide and/or said vector. Also, the present invention relates to methods, kits, and uses related thereto.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Abstract: A method for the identification of compounds modulating the biological activity of FGF2, the method comprising the use of target cells sensitive to the presence of FGF2 by obstructing proliferation, wherein the target cells constitutively express a first reporter in- the nucleus of living target cells.

Abstract: The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.

Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.

Abstract: A light source device including a light emitting element for emitting a light having the following characteristics: a wavelength ranging from 435 to 520 nm, and a power density greater than 20 mW/cm2, the light source device provides an effective fluence to any contaminating and/or pathogenic agent greater than 11 J/cm2. Also, a light source assembly including a product adapted to be in contact with a support or a medium, preferably the skin or a wound and a light source device connected to the product for providing light to at least one contaminating and/or pathogenic agent present on a support or in a medium.

Abstract: An imaging method for radiologically guiding an instrument during medical interventions on an object is disclosed. First, a prior volumetric image of the object is provided, followed by periodically providing a current volumetric image on-the-fly during the intervention to an operator by measuring an undersampled set of projections of the object and reconstructing the current image based on changes between the prior volumetric image or an updated prior image and the undersampled set of projections. The method and corresponding system are used for radiologically guiding medical interventions on an object. The system includes a first image provider, an imaging apparatus for measuring undersampled sets of projections, and a processor. The processor communicates with the imaging apparatus for providing updated images on-the-fly during the intervention by reconstructing the updated image based on changes between the first image or an update of the first image and the undersampled sets of projections.

Abstract: A body fluid leakage detection aqueous composition, for use e.g. in intraoperative pancreatic fluid leakage detection. The composition comprises a gelling agent, increasing the viscosity of the composition, and buffering species, the composition thereby being buffered. The gelling agent is cross-linked ?-glucan microspheres. Further, the composition comprises a pH-indicator. The pH of the composition is at least 0.1 pH units lower, or higher, than a pKa of the pH-indicator.

Abstract: The present invention relates to compositions for the treatment of a malignant disease and in particular to compositions comprising an NF-?B inhibitor and a ?-glutamyltransferase (?-GT) inhibitor and therapeutic uses thereof. The invention further relates to in vitro methods of testing putative anti-tumour agents for their potential to act as therapeutically effective anti-tumour agents in vivo. Embodiments of the invention have been particularly developed for bringing NF-?B inhibitors to the clinic such as to provide alternative therapeutic options in the treatment of malignant diseases and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.

Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

Abstract: The present invention relates to S100 protein and nuclei acids encoding S100 protein for enhancing the cardiac power as well as vectors and pharmaceuticals comprising the same and uses thereof.

Abstract: The present invention relates to liposomal compositions, comprising liposomes containing tetraether lipids (TELs), and further comprising the lipopeptide Myr-HBVpreS/2-48 (Myrcludex B) as part of said liposomes, as well as uses thereof for the prevention or treatment of hepatic disorders or diseases, and/or for the oral hepatic delivery of therapeutic and/or diagnostic agents.

Abstract: Multispectral imaging of samples, in particular of biological tissues. A method for acquisition of fluorescence images and reflection images of an object including alternatingly illuminating the object with at least a first light and a second light, wherein the first light and the second light are spectrally shaped such that at least one light has several spectral regions of high light intensity separated by spectral region(s) of low light intensity, wherein the spectral regions of the first light and the second light with high intensity at least partially do not overlap and wherein at least one of the two lights has at least one region of low light intensity that is of longer wavelength to the neighboring region of high light intensity, and recording at least a first image of the object and a second image of the object while illuminating the object with at least one of the lights.

Abstract: Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.